3D Molecular Sciences presented a poster providing new assay data on the Company’s multiplexing enabling platform technology for molecular medicine at the BioArray Europe conference, taking place in Cambridge, UK, on 1 October 2002. The new patented assay system consists of microfabricated encoded particles of a variety of designs, attachment chemistries and a choice of readers to interpret the results.

The poster presentation, entitled Several Assay Systems Presented Using a New Patented 3D Encoded Particle Array Tool for Multiplexing Bioassays, shows new data demonstrating the compatibility of the Company’s individually coded particles with a diverse range of assays including nucleic acids and cytokines. The Company’s technology platform offers an inexpensive and flexible tool to the pharmaceutical, biotech and clinical diagnostic industries that allows for a superior volume of tests, a scaleable capability and multiplexing of samples. It has the potential to screen for gene-linked diseases such as cancer, Alzheimer`s, obesity and cystic fibrosis. It can also offer great possibilities in compound library screening, environmental monitoring and in anti-terrorism systems.

Dr Elizabeth Hill, 3D Molecular Sciences’ CEO, said, “Our 3DMS™ 3D particle array tools are designed to carry out large-scale bioassay analysis required in drug discovery, drug development and in diagnostics in a low cost and fast manner. Our data presented at this conference clearly illustrates the capability this platform has, and we will continue to maintain our technology programme so we can exploit this platform to the full.”

The Company’s 3DMS™ particle array system is a new, patented assay and detection technology that uses individually microscopic encoded particles for the detection of biological content or biochemical interactions in a wide variety of analytical bioassays and test formats. Such formats are for proteomics, immunoassays gene expression and SNP analysis.

Work is currently underway on a number of further commercial assay systems to illustrate the 3DMS 3D-particle array capability. The Company has a strong patent position and welcomes the opportunity to discuss licensing and collaboration with commercial partners to build and develop this platform further with suitable commercial assay applications.